ArticleJournal of the anus, rectum and colon2025
Fibrinogen-Albumin Ratio: An Independent Recurrence Factor for Colorectal Cancer Stages II and III in a Competing Risk Model.
Article in Journal of the anus, rectum and colon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Colorectal cancer remains a major global health concern. Identifying high-risk patients is crucial for optimizing treatment strategies. The prognostic value of biomarkers, especially considering competing risks, remains unclear. We used a competing risks model to exclude the influence of non-cancer-related mortality and examined FAR as a predictor of recurrence in colorectal cancer. Methods: This retrospective study analyzed 359 patients with stage II or III colorectal cancer from the cecum to the oral side of the peritoneal inversion, all of whom underwent curative resection at Fukui University Hospital. The primary outcome was cancer recurrence. The fibrinogen-albumin ratio (FAR) was assessed using univariate and multivariate analyses, including competing risk models, with a cutoff value of >0.131. Results: Univariate analysis identified factors significantly associated with poorer outcomes, including T4 stage, gross appearance type 3/4/5 tumors, stage III disease, elevated neutrophil-to-lymphocyte ratio, prognostic nutritional index, carcinoembryonic antigen, and FAR. Multivariate analysis confirmed FAR as an independent prognostic factor. A predictive model combining FAR, stage III disease, and T4 stage demonstrated the best performance based on Akaike information criterion and Bayesian information criterion values. Conclusions: FAR is a robust prognostic biomarker for colorectal cancer. Incorporating FAR into clinical practice may enable healthcare providers to more accurately stratify high-risk patients, facilitating personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.